Puli Pharmaceutical's Sodium Nitroprusside Injection has been approved for market in Saudi Arabia, r

Puli Pharmaceutical's Sodium Nitroprusside Injection has been approved for market in Saudi Arabia, receiving the third approval from Saudi Arabia! Puli Pharmaceutical's Sodium Nitroprusside Injection has been approved for market in Saudi Arabia! Hainan Puli Pharmaceutical Co., Ltd. (hereinafter referred to as "Puli Pharmaceutical" or "the Company") recently received marketing authorization for sodium nitroprusside injection (specification: twoml: fiftymg) issued by the Saudi Arabian Food and Drug Administration (hereinafter referred to as "SFDA"). This marks Puli Pharmaceutical's qualification to sell sodium nitroprusside injection in Saudi Arabia, which will have a positive impact on the company's expansion into the Saudi Arabian market. Sodium nitroprusside injection is a classic vasodilator mainly used for hypertension emergencies and acute heart failure. It has been included in the list of essential and emergency drugs in clinical practice. Sincere invitation for cooperation, international investment: Mr. Zhou. The future prospects of Saudi Arabia's pharmaceutical market are promising. Saudi Arabia is located in the Arabian Peninsula, bordering countries such as the United Arab Emirates, Jordan, Iraq, and Kuwait, and is one of the largest economies in the Middle East. Saudi Arabia's gross domestic product (GDP) in two thousand twenty-three will be one thousand sixty-seven.five billion US dollars (the seventh in Asia), and its per capita GDP will be about thirty-two thousand US dollars (the tenth in Asia), two.five times that of China and equivalent to that of Japan. According to FutureMarketInsights, the pharmaceutical market in Saudi Arabia is estimated to be valued at approximately $ten.one billion in two thousand twenty-four and is projected to reach $sixteen.eight billion by two thousand thirty-four, with a compound annual growth rate (CAGR) of five.twenty%. This indicates that Saudi Arabia's pharmaceutical market will maintain stable growth in the next decade. Sincere invitation for cooperation, international investment: Mr. Zhou. two. Puli Pharmaceutical's nitroprusside injection/nitroprusside sodium chloride injection has been deployed in eleven countries or regions. As of now, Puli Pharmaceutical's nitroprusside injection has been approved in China, the United States, Canada, Australia, Germany, Austria, Saudi Arabia and other countries or regions. In addition, the countries or regions under review for Puli Pharmaceutical's sodium nitroprusside injection include the United Kingdom, Hong Kong, and Thailand. Sodium nitroprusside and sodium chloride injection have been approved in the United States. Sincere invitation for cooperation, international investment: Mr. Zhou. Regarding Puli Pharmaceutical, founded in Haikou in one thousand nine hundred and ninety-two, Puli Pharmaceutical is a leading enterprise in the internationalization of Chinese pharmaceutical preparations and a demonstration enterprise for intelligent manufacturing by the Ministry of Industry and Information Technology. It has been included in the key project of Made in China two thousand twenty-five for industrial transformation and upgrading by the Ministry of Industry and Information Technology. In two thousand twenty-three, Puli Pharmaceutical in Hainan passed the "AEO" advanced certification by customs. Previously, Hainan Puli and its subsidiaries Zhejiang Puli and Anhui Puli have also successfully passed on-site audits by the US FDA and EU EMA multiple times. As a leading enterprise in the internationalization of Chinese pharmaceutical preparations, Puli Pharmaceutical has been adhering to high global quality standards for many years. It is one of the few domestic platforms for the research and production of active pharmaceutical ingredients and injections, and also one of the few high-quality suppliers of active pharmaceutical ingredients, key excipients, pharmaceutical drugs, and GMP intermediates CMO/CDMO approved by drug regulatory authorities in the United States, China, and the European Union. (Puli Pharmaceutical)